Zogenix (ZGNX)

[TRUISM]

Analyst Rating Update on Zogenix, Inc.
Phil Early July 10, 2015
Click For Link



Research firm Zacks has rated Zogenix Inc (NASDAQ:ZGNX) and has ranked it at 3, indicating that for the short term the shares are a hold. 6 Wall Street analysts have given the company an average rating of 1.33. The shares has received a hold rating based on the suggestion from 1 analysts in latest recommendations. Strong buy was given by 5 Wall Street Analysts.

Company has received price target recommendation from many analysts. Piper Jaffray initiates coverage on Zogenix, Inc. (NASDAQ:ZGNX). In the latest research report, Piper Jaffray announces the target price to $2.5 per share on the shares. According to the latest information available, the shares are now rated Overweight by the analysts at the agency. The rating by the firm was issued on April 22, 2015.

Zogenix, Inc. (NASDAQ:ZGNX): According to 5 Analysts, The short term target price has been estimated at $ 22.4.The target price could deviate by a maximum of $3.58 from the forecast price. In the near term, the target price could hit a high of $28 and a low of $ 20.

Zogenix, Inc. (NASDAQ:ZGNX) : On Thursday heightened volatility was witnessed in Zogenix, Inc. (NASDAQ:ZGNX) which led to swings in the share price. The shares opened for trading at $13.16 and hit $13.36 on the upside , eventually ending the session at $13.22, with a gain of 1.85% or 0.24 points. The heightened volatility saw the trading volume jump to 725,397 shares. The 52-week high of the share price is $15.68 and the company has a market cap of $253 million. The 52-week low of the share price is at $8.56 .

Zogenix, Inc. has dropped 5.3% in the last five trading days, however, the shares have posted positive gains of 1.38% in the last 4 weeks. Zogenix, Inc. is up 11.66% in the last 3-month period. Year-to-Date the stock performance stands at 20.62%.

Zogenix, Inc. (Zogenix) is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Its lead product candidate, Zohydro (hydrocodone bitartrate, formerly ZX002) is a 12-hour extended-release formulation of hydrocodone without acetaminophen for the treatment of chronic pain requiring opioid therapy.

It completed Phase 3 development of Zohydro in 2011. Its second DosePro investigational product candidate, Relday, is a injectable formulation of risperidone for the treatment of schizophrenia. In April 2014, Endo International PLC acquired worldwide rights to Sumavel DosePro (sumatriptan injection) for subcutaneous use, a needle-free delivery system for sumatriptan, from Zogenix, Inc.




Blessings to All

TRUTH